A phase 3 study of XP23829 in patients with chronic plaque-type psoriasis

Trial Profile

A phase 3 study of XP23829 in patients with chronic plaque-type psoriasis

Planning
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2015

At a glance

  • Drugs XP 23829 (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Dr Reddys Laboratories
  • Most Recent Events

    • 17 Sep 2015 New trial record
    • 15 Sep 2015 According to XenoPort media release, company expects to start this trial by 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top